New Drug: Pirtobrutinib in Mantle Cell Lymphoma
Study
| Open-label, multicenter, single-arm trial (BRUIN) |
| Mantle cell lymphoma previously treated with a BTK inhibitor |
| Pirtobrutinib (n=120) |
Efficacy
| ORR: 50% [41-59] |
| DoR: 8.3 mos [5.7 mos-NR] |
| 6 mos DoR: 65.3% [49.8-77.1] |
Safety
| Grade 3 AEs: Neutropenia (>10%), Lymphopenia (>10%), thrombocytopenia (>10%) |
Article not yetpublished
http://www.ncbi.nlm.nih.gov/pubmed/0
Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023
